A written Barron's stock pick (no video), so the "At" column links to the article. BMW uses its home-listing symbol (BMW.DE, Xetra) with QT/SA pointed at the OTC ADR (BMWKY, one-third of a share). BYD is the share-taker in China (hub id 1211.HK, ADR BYDDY); Tesla and GM are argued valuation/capital-return comparisons. Ford is a one-word market-cap comparison and is not rowed. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis.
| Ticker | Name | Research | View | What the article said | At |
|---|---|---|---|---|---|
| BMW.DE | Bayerische Motoren Werke (BMW) | QT · SA · STK | Positive | Barron's Stock Pick. Down 35% to €61 on a China-driven profit warning, but "one of the best-run auto makers in the world": ~9x trough 2026 EPS (€6.5 → €8 in 2027), 40% of book, $42B value (less than GM or Ford), ~€100/share of net cash + financial assets + finance-arm book. Capex falling, 8,000 layoffs, Neue Klasse EV platform; late-Sept capital markets day could lift payout to 40–50% and buybacks. Third Avenue: "existential risk priced into the stock." | read ↗ |
| 1211.HK | BYD Company | QT · SA · STK | Neutral | The named Chinese domestic manufacturer taking share from European luxury-car makers in China — the reason BMW's Chinese sales fell 30% in Q2 and it issued its June profit warning. Context for the bear case, no stance on BYD. | read ↗ |
| TSLA | Tesla | QT · SA · STK · FA | Neutral | The industry's valuation outlier: a $1.4 trillion market value driven by robots, autonomy and robo-taxis rather than cars — it "will earn little more than BMW this year and has 30 times its market value." Used to show how cheaply the car business itself is priced. | read ↗ |
| GM | General Motors | QT · SA · STK · FA | Neutral | The capital-return template: BMW buys back over €1B a year (~3% of market value) but "has the wherewithal to get more aggressive in the way that General Motors has done." Also worth more than BMW's $42B. No stance on GM. | read ↗ |
A jargon-free summary of how each name is framed in the article. (Plain-language companion to the table above; renders on each ticker's consolidated page.)
BMW's shares have fallen by about a third this year, to a price lower than a decade ago. The main reason is China: local brands like BYD are winning customers from European luxury makers, BMW's Chinese sales dropped 30%, and the company warned its 2026 profits would disappoint.
Barron's argues investors have gone too far. This year is likely the low point for profits, the heavy spending on its new electric-car platform is done, and it is cutting costs. Meanwhile the balance sheet is unusually strong: counting its car business's net cash, other financial assets, and the value of its car-loan arm, there's roughly €100 of value per share behind a €61 stock. Put differently, the market is paying about 9 times a bad year's earnings and 40 cents per euro of book value.
A possible spark is BMW's investor day in late September, where it may promise to pay out more of its profit as dividends and buy back more stock. U.S. investors can buy the over-the-counter ADR, BMWKY (each worth a third of a German share).
BYD, China's biggest electric-car maker, appears as the competitor behind BMW's troubles in China — local manufacturers like it are taking market share from European luxury brands. The article takes no view on BYD's stock; it's the "why" of BMW's profit warning.
Tesla is used as a contrast. It's worth about $1.4 trillion — 30 times BMW — yet will earn only a little more than BMW this year, because investors are paying for robots, self-driving and robo-taxis rather than car sales. The point: ordinary car-making is priced very cheaply, and BMW is priced cheaply even among car makers.
General Motors is the example of what BMW could do with its cash: GM has aggressively bought back its own shares, and Barron's says BMW could follow that playbook as its spending falls. GM is also cited as being worth more than BMW. No recommendation on GM itself.
Summary derived from the Barron's article (full text saved in transcript.txt) for personal study. Not investment advice. © Barron's / Dow Jones for source material.